Recent developments for Pseudomonas vaccines. Review uri icon

Overview

MeSH

  • Animals
  • Biomedical Research
  • Clinical Trials as Topic
  • Cystic Fibrosis
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Immunity, Mucosal
  • Immunocompromised Host

MeSH Major

  • Pseudomonas Infections
  • Pseudomonas Vaccines
  • Pseudomonas aeruginosa

abstract

  • Infections with Pseudomonas aeruginosa are a major health problem for immune-compromised patients and individuals with cystic fibrosis. A vaccine against: P. aeruginosa has long been sought after, but is so far not available. Several vaccine candidates have been assessed in experimental animals and humans, which include sub-cellular fractions, capsule components, purified and recombinant proteins. Unique characteristics of the host and the pathogen have complicated the vaccine development. This review summarizes the current state of vaccine development for this ubiquitous pathogen, in particular to provide mucosal immunity against infections of the respiratory tract in susceptible individuals with cystic fibrosis.

publication date

  • October 2011

has subject area

  • Animals
  • Biomedical Research
  • Clinical Trials as Topic
  • Cystic Fibrosis
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Immunity, Mucosal
  • Immunocompromised Host
  • Pseudomonas Infections
  • Pseudomonas Vaccines
  • Pseudomonas aeruginosa

Research

keywords

  • Journal Article
  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3360073

Digital Object Identifier (DOI)

  • 10.4161/hv.7.10.16369

PubMed ID

  • 21941090

Additional Document Info

start page

  • 999

end page

  • 1011

volume

  • 7

number

  • 10